Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Geurts BS, Battaglia TW, van Berge Henegouwen JM, Zeverijn LJ, de Wit GF, Hoes LR, van der Wijngaart H, van der Noort V, Roepman P, de Leng WWJ, Jansen AML, Opdam FL, de Jonge MJA, Cirkel GA, Labots M, Hoeben A, Kerver ED, Bins AD, Erdkamp FGL, van Rooijen JM, Houtsma D, Hendriks MP, de Groot JB, Verheul HMW, Gelderblom H, Voest EE. Geurts BS, et al. Among authors: houtsma d. BMC Cancer. 2023 Mar 4;23(1):205. doi: 10.1186/s12885-023-10663-2. BMC Cancer. 2023. PMID: 36870947 Free PMC article.
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H; Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Huober J, et al. JAMA Oncol. 2023 Oct 1;9(10):1381-1389. doi: 10.1001/jamaoncol.2023.2909. JAMA Oncol. 2023. PMID: 37561451
Pharmacogenetics in oncology: a promising field.
Houtsma D, Guchelaar HJ, Gelderblom H. Houtsma D, et al. Curr Pharm Des. 2010;16(2):155-63. doi: 10.2174/138161210790112719. Curr Pharm Des. 2010. PMID: 20205661 Review.
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Fontein DB, Houtsma D, Nortier JW, Baak-Pablo RF, Kranenbarg EM, van der Straaten TR, Putter H, Seynaeve C, Gelderblom H, van de Velde CJ, Guchelaar HJ. Fontein DB, et al. Among authors: houtsma d. Breast Cancer Res Treat. 2014 Apr;144(3):599-606. doi: 10.1007/s10549-014-2873-2. Epub 2014 Mar 4. Breast Cancer Res Treat. 2014. PMID: 24590773 Clinical Trial.
Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers.
Verhaart SL, Abu-Ghanem Y, Mulder SF, Oosting S, Van Der Veldt A, Osanto S, Aarts MJB, Houtsma D, Peters FPJ, Groenewegen G, Van Herpen CML, Pronk LM, Tascilar M, Hamberg P, Los M, Vreugdenhil G, Polee M, Ten Tije AJ, Haanen JBAG, Bex A, van den Eertwegh AJ. Verhaart SL, et al. Among authors: houtsma d. Clin Genitourin Cancer. 2021 Jun;19(3):274.e1-274.e16. doi: 10.1016/j.clgc.2020.10.003. Epub 2020 Oct 14. Clin Genitourin Cancer. 2021. PMID: 33317946
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.
Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, Houterman S, Koolen SLW, Bins S, Thijs AMJ, Laven MMJ, Hövels AM, Luelmo SAC, Houtsma D, Shulman K, McLeod HL, van Schaik RHN, Guchelaar HJ, Mathijssen RHJ, Gelderblom H, Deenen MJ. Hulshof EC, et al. Among authors: houtsma d. Eur J Cancer. 2022 Feb;162:148-157. doi: 10.1016/j.ejca.2021.12.009. Epub 2022 Jan 5. Eur J Cancer. 2022. PMID: 34998046 Free article.
Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia - a randomized controlled trial.
Lugtenberg RT, van den Hurk CJG, Smorenburg CH, Mosch L, Houtsma D, Deursen MAGDH, Kaptein AA, Gelderblom H, Kroep JR. Lugtenberg RT, et al. Among authors: houtsma d. Support Care Cancer. 2022 Aug;30(8):6641-6648. doi: 10.1007/s00520-022-07090-7. Epub 2022 May 2. Support Care Cancer. 2022. PMID: 35501515 Free PMC article. Clinical Trial.
Phase 1 Study to Evaluate the Safety of Reducing the Prophylactic Dose of Dexamethasone around Docetaxel Infusion in Patients with Prostate and Breast Cancer.
Lugtenberg RT, de Groot S, Houtsma D, Dezentjé VO, Vulink AJE, Fischer MJ, Portielje JEA, van der Hoeven JJM, Gelderblom H, Pijl H, Kroep JR. Lugtenberg RT, et al. Among authors: houtsma d. Cancers (Basel). 2023 Mar 9;15(6):1691. doi: 10.3390/cancers15061691. Cancers (Basel). 2023. PMID: 36980577 Free PMC article.
26 results